Literature DB >> 8996327

Osteoporosis after orchiectomy for prostate cancer.

H W Daniell1.   

Abstract

PURPOSE: The possibility of increased osteoporosis and osteoporotic fractures following therapeutic orchiectomy in men with prostate cancer was investigated.
MATERIALS AND METHODS: A total of 235 men with nonstage A prostate cancer diagnosed between 1983 and 1990 was analyzed for therapeutic orchiectomy, other osteoporotic risk factors and subsequent hospital treatment for osteoporotic fractures. The 17 castrated men alive in 1995 were interviewed, and femoral neck bone mineral density was compared to that of 23 controls of similar age.
RESULTS: Risk factors for osteoporosis, including smoking, slender habitus and atrophic testes, were common among men treated with orchiectomy. Of the men in the study cohort 10 had osteoporotic fractures: 8 of 59 treated with and 2 of 176 without orchiectomy (13.6 versus 1.1%, p < 0.001). First fracture cumulative incidence rates 7 years after castration or diagnosis were 28 and 1%, respectively (p < 0.001). Osteoporotic fractures were much more common than pathological fractures or those due to major trauma (1 each). Bone mineral density averaged 0.91, 0.84, 0.79 and 0.66 gm./cm.2 in 9 controls without prostate cancer, 14 men with prostate cancer before orchiectomy, 9 men at 9 to 60 and 8 men at 60 to 115 months after orchiectomy, respectively. Of the 16 men surviving for longer than 60 months after orchiectomy 6 had osteoporotic fractures, as did 5 of 6 and 5 of 7 with a bone mineral density of less than 0.70 gm./cm.2 and less than 75% of normal for age, respectively.
CONCLUSIONS: Orchiectomy for prostate cancer is frequently followed by severe osteoporosis, some of which had developed before castration. Appropriate therapy should be identified that does not diminish the antitumorigenic effectiveness of androgen ablation.

Entities:  

Mesh:

Year:  1997        PMID: 8996327

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  58 in total

Review 1.  Osteoporosis in men.

Authors:  G M Prelevic
Journal:  J R Soc Med       Date:  2001-12       Impact factor: 5.344

Review 2.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 3.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

4.  Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone.

Authors:  Olga Zolochevska; Jayne Ellis; Sangram Parelkar; Delphine Chan-Seng; Todd Emrick; Jingna Wei; Igor Patrikeev; Massoud Motamedi; Marxa L Figueiredo
Journal:  Hum Gene Ther       Date:  2013-11-06       Impact factor: 5.695

Review 5.  Discovery and therapeutic promise of selective androgen receptor modulators.

Authors:  Jiyun Chen; Juhyun Kim; James T Dalton
Journal:  Mol Interv       Date:  2005-06

6.  Preventing skeletal complications in androgen deprived men with prostate cancer: Time for action.

Authors:  M Braga-Basaria; S Basaria
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

7.  Adverse events associated with hormonal therapy for prostate cancer.

Authors:  Ravi J Kumar; Al Barqawi; E David Crawford
Journal:  Rev Urol       Date:  2005

Review 8.  The role of estrogen and androgen receptors in bone health and disease.

Authors:  Stavros C Manolagas; Charles A O'Brien; Maria Almeida
Journal:  Nat Rev Endocrinol       Date:  2013-09-17       Impact factor: 43.330

Review 9.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

Review 10.  Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.